[1]Zhang H. Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Ther, 2015, 9(11):6075-6081.
[2]Qin SK, Li J. Experts consensus on the clinical application of apatinib in gastric cancer treatment[J]. Chin Clin Oncol, 2015, 20(9):841-847.
[3]鲁丁瑜,李娜,李志平.多靶点抗肿瘤新药阿帕替尼的研究进展[J].华西药学杂志,2017,32(1):104-108.
[4]朱丹,赵宏伟,赵健琦,等.肿瘤分子靶向药物阿帕替尼的临床研究进展[J].中国医院药学杂志,2017,37(2):194-198.
[5]陈淑慧,阳帆帆,何君,等.胃癌靶向治疗研究最新进展[J].中国临床药理学与治疗学,2015,20(8):950-955.
[6]武健,尹芳,罗贯虹,等.经肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性分析[J].临床肝胆病杂志,2018(4):775-778.
[7]宋锦添,陈奕贵,许春伟,等.阿帕替尼治疗53例晚期原发性肝癌的疗效[J].临床与病理杂志,2017,37(3):557-563.
[8]刘凯,毋永娟.靶向药物阿帕替尼三线治疗晚期乳腺癌单臂、单中心Ⅱ期临床研究[J].医学理论与实践,2017,30(3):320-322.
[9]Ding J, Chen X, Dai X, et al. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chroma- tography- tandem mass spectrometry and its application to a pharmacokineticstudy[J]. J Chromatogr B,2012, 895(7):108-115.
[10]Zhou Y, Wang S, Ding T, et al. Evaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC-MS/MS[J]. J Chromatogr B, 2014, 973: 68-75.
[11]南峰, 徐楠, 陈枳潓,等.快速灵敏的LC-MS/MS法测定人血浆中阿莫西林并应用于两种制剂的一致性评价[J].中国临床药理学与治疗学,2018,23(1):73-77.
[12]李力,李贺,黄越,等.LC-MS/MS同时测定大鼠血浆中5种银杏酸浓度及其药动学研究[J].中国现代应用药学,2017,34(12):1658-1662.
[13]Widmer N,Bardin C,Chatelut E,et al. Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies[J]. Eur J Cancer,2014,50: 2020 -2036.
[14]Mai H, Huang J, Zhang Y, et al. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study[J]. Oncotarget, 2017, 8(26): 43458.
[15]Fukudo M,Ito T,Mizuno T,et al. Exposure - toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma[J].Clin Pharmacokinet,2014, 53: 185-196.
[16]Tandia M, Mhiri A, Paule B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study[J]. Cancer Chemoth Pharm, 2017, 79(4): 759-766.
[17]Widmer N,Bardin C,Chatelut E,et al. Review of therapeutic drug monitoring of anticancer drugs part two -targeted therapies[J]. Eur J Cancer,2014,50: 2020-2036.
[18]Fukudo M,Ito T,Mizuno T,et al. Exposure- toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma[J].Clin Pharmacokinet,2014, 53: 185 -196.
[19]时佳琪,刘超,张艳桥,等.甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析[J].中国肿瘤临床,2018,45(4):191-195.
|